Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia

Purpose We evaluated the population pharmacokinetics (PPK) and exposure–response relationship of imatinib mesylate in Iranian patients with chronic myeloid leukemia (CML).This study was designed to assess steady state (SS) imatinib trough concentrations (Cmin) and pharmacokinetics parameters of imatinib in patients with CML in chronic phase after at least 12-month treatment.